PALO ALTO, CA - November 30th, 2021 : CSL, one of the world’s leading biotech companies, announced today it will be collaborating with StartX, the industry and stage-agnostic community of founders based in Silicon Valley, as an Innovation Partner over a two-year program.
Through this partnership CSL, which treats patients with rare and serious diseases and protects human health through influenza vaccines in more than 100 countries, will seek to support entrepreneurs in the StartX community as they commercialize innovative technologies and develop novel therapeutics. By providing access to commercial, R&D, clinical, intellectual property, marketing and manufacturing expertise, CSL will work with the StartX community to accelerate the start-up trajectory and deliver outcomes to patients faster.
Similarly, the partnership will further one of CSL’s innovation goals of broadening and diversifying its R&D portfolio through strategic partnering with biotech incubators, accelerators and entrepreneurial ecosystems.
“As an organization that is driven by our promise to patients, CSL is, excited to join the StartX community which is located in one of the most intensive and successful innovation clusters in the world. Combined with our research site in Pasadena, we look forward to being an innovation partner to the StartX community, contributing to what makes it such a unique network of successful entrepreneurs and establishing further relationships across the US West Coast,” said CSL’s Head of Global Research Innovation, Dr Marthe D’Ombrain.
The goal of the partnership between StartX and CSL is to build a strong and long-lasting relationship promoting innovation and technology breakthroughs that can change the lives of patients around the world. Dr. D’Ombrain added, “The interconnected network and the depth of support offered throughout the community is what appeals to CSL and is strongly aligned with our values and purpose. We look forward to creating long-term mutual partnerships to further innovation, and hope to help transform ideas into ground-breaking therapies, leading to a stronger pipeline of new medicines that will ultimately address unmet medical needs for patients.”
“At StartX, we are excited for the opportunity to have the full force of the StartX Med startup community available to help achieve CSL’s innovation goals for 2022. I am very impressed with the collaboration between our Innovation team and CSL’s Research Innovation team as we set the stage for two key strategic summits in the new year. The entire purpose of our industry Innovation Partnerships program is for StartX Med technology breakthroughs to maximize their impact on as many patients as possible, and, through this innovation partnership, the CSL team is doing all the right things to achieve this,” commented StartX CEO, Joseph Huang.
Each year, CSL works to identify promising research programs across the globe which will benefit most from industry collaboration and support.
### - ENDS - ###
About CSL
CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 100 countries and employs more than 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.
For more information visit www.csl.com.